AKT1 and ulcerative colitis: The molecular docking analysis revealed promising binding affinities of ten BRLE bioactive compounds against four key ulcerative colitis-related targets (EGFR, SRC, STAT3, and AKT1), with binding scores ranging from −6.5 to −9.1 kcal/mol.